Study details
Enrolling now
Defibrotide for Severe COVID-19
Brigham and Women's Hospital
NCT IDNCT04652115ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
42
Study length
about 4.2 years
Ages
18–100
Locations
1 site in MA
What this study is about
Researchers are testing if defibrotide, a medication, can be safely used in people with severe COVID-19 pneumonia. The trial will evaluate the safety and feasibility of using this treatment in hospitalized patients who need oxygen or mechanical ventilation.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Defibrotide
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
defibrotide
Endpoints
Primary: The rate of adverse event of special interest (bleeding and hypotension)
Body systems
Infectious